DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
CB-839 is an investigational drug.
There have been 21 clinical trials for CB-839. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Novotech (Australia) Pty Limited.
There are sixteen US patents protecting this investigational drug and one hundred and twenty-four international patents.
Recent Clinical Trials for CB-839
|Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects||Novotech (Australia) Pty Limited||Phase 1|
|Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects||Calithera Biosciences, Inc||Phase 1|
|A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC||Calithera Biosciences, Inc||Phase 2|
Top disease conditions for CB-839
Top clinical trial sponsors for CB-839
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CB-839||Get Started for $10||Combination therapy with glutaminase inhibitors||Calithera Biosciences, Inc. (South San Francisco, CA)||Get Started for $10|
|CB-839||Get Started for $10||Compositions and methods of treating cancer harboring PIKC3A mutations||Case Western Reserve University (Cleveland, OH)||Get Started for $10|
|CB-839||Get Started for $10||Combination therapy with glutaminase inhibitors and immuno-oncology agents||Calithera Biosciences, Inc. (South San Francisco, CA)||Get Started for $10|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CB-839||China||CN109982703||2036-08-25||Get Started for $10|
|CB-839||European Patent Office||EP3503893||2036-08-25||Get Started for $10|
|CB-839||Japan||JP2019524852||2036-08-25||Get Started for $10|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|